PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-1.81
Negative P/E while Biotechnology median is -4.85. Seth Klarman would scrutinize path to profitability versus peers.
No Data
No Data available this quarter, please select a different quarter.
2.70
P/B 50-90% of Biotechnology median of 3.41. Mohnish Pabrai would examine if this discount presents opportunity.
-11.40
Negative FCF while Biotechnology median P/FCF is -20.61. Seth Klarman would investigate cash flow improvement potential.
-11.45
Negative operating cash flow while Biotechnology median P/OCF is -20.23. Seth Klarman would investigate operational improvement potential.
2.70
Fair value ratio 50-90% of Biotechnology median of 3.41. Mohnish Pabrai would examine if this gap presents opportunity.
-13.79%
Negative earnings while Biotechnology median yield is -3.03%. Seth Klarman would investigate path to profitability.
-8.77%
Negative FCF while Biotechnology median yield is -1.98%. Seth Klarman would investigate cash flow improvement potential.